Breast cancer: Good news, bad news
Women who survive breast cancer for at least five years have a 89% chance that it will not recure. But those, who are still suffering and on endocrine treatment are likely to get arthralgia and arthritis.
Chemotherapy
CRC-report shows urgent need for action
Limited public and political awareness of colorectal cancer (CRC), few formal screenings programms, delayed access to treatment - the first cross-country report on the management and funding of colorectal cancer (CRC) reveals an urgent need for action to improve the survival of patients in Europe and Australia.
Multiple-targeted therapies
The next big development in biological targeted therapies for advanced breast cancer will be drugs acting via multiple mechanisms, experts told delegates attending the 1st Asian Breast Cancer conference, held in New Delhi 9-10 February.
German Radiology Congress 2008
Along with paediatric radiology, interventional radiology will have a high profile at the 89th German Radiology Congress and 5th Joint Congress with the Austrian Radiology Society. Congress presidents Professor Dierk Vorwerk and Professor Richard Fotter outlined what's on the agenda for the expected 6,900 visitors. Training, they pointed out, will aim at those preparing to specialise in…
Personalised medicine?
'How do you treat the HIV-positive, diabetic, schizophrenic patient presenting with chest pain? By making the necessary information available for personalised medicine'
Open High-field MRI
As part of a research and development project, doctors at the University Hospital Magdeburg, Germany, are treating oncology patients with local minimally invasive surgery (MIS) which, for the first time, can be carried out under radiological image control using high-field magnetic resonance imaging (MRI). The system offers excellent image quality under extremely favourable, radiation-free…
A website for breast cancer patients
For women (or friends and relatives of women with breast cancer),
Effectiveness of multidrug combinations for chemotherapy
Professor Loennidis, University of Ioannina School of Medicine, Greece, and a team of researchers examined 242 randomized trials, performed during the last fourty years and covering the efficiacy of chemotherapy treatment for advanced stages of colorectal cancer. The scientist compared the benefits and outcome of different systemic treatment regimes.
European Institute of Molecular Imaging founded in Münster, Germany
Besides sophisticated imaging technologies, biomarkers are the key to molecular medicine. Therefore, the development of new and more specific biomarkers is the primary aim of researchers around the world and - since this June - it is also the aim of the new founded European Institute of Molecular Imaging, a cooperation project of the University Münster, Germany and Siemens Medical Solutions.…
For use with microscopes
The new Olympus E-330 micro-imaging system for microscopy includes the world's first digital SLR camera to show real-time frame images on the LCD, the company reports. `The system is based around a 7.5 Megapixel sensor, which together with an array of unique features delivers incredibly sharp and vibrant images directly onto a 2.5 inch high-resolution colour LCD. Other features of the micro…
Hormone-resistant prostate cancer
Prostate cancer, the most common neoplasm in men, often progresses from an androgen-dependant state (and is commonly treated by androgen ablation therapies) to a hormone-refractory stage, therefore making hormone therapy ineffective. The response duration to androgen ablation therapy is finite and ultimately most prostate cancer will become hormone-insensitive.
Article • Focus on treatment and research news
Chemotherapy: effective against cancer, at a cost
Chemotherapy is used against various cancers and is often consideres as a last resort – especially if the cancer has metastasised. Since chemotherapy agents can cause severe side effects, research aims to make treatment more tolerable. Keep up-to-date with the latest research news, medical applications, and background information.